checkAd

    DGAP-News  785  0 Kommentare Sangui BioTech International Inc.: SastoMed closes contracts with distribution partners in six additional markets in Eastern Europe


    DGAP-News: Sangui BioTech International Inc. / Key word(s): Market
    launch
    Sangui BioTech International Inc.: SastoMed closes contracts with
    distribution partners in six additional markets in Eastern Europe

    03.02.2015 / 15:00

    ---------------------------------------------------------------------

    SanguiBioTech: SastoMed closes contracts with distribution partners in six
    additional markets in Eastern Europe

    Witten, Germany, February 3, 2015 - SastoMed GmbH has informed Sangui of
    having closed contracts for initiating distribution and sales of the Sangui
    developed dressing material Granulox in six Eastern European countries. In
    2015 the three Baltic countries will join the family of Granulox
    territories along with the Czech Republic, Slovakia and Hungary.

    Like in three Scandinavian markets it will be an enterprise belonging to
    the Mediq group which will start initiating the distribution in Estonia,
    Latvia and Lithuania. Mediq Eesti OÜ (www.mediq.ee) is a wholesale company
    which has been successfully trading medical and health care products
    throughout the Baltic countries for many years. Its core business is in
    medical products and laboratory equipment. A care a.s.
    (http://www.acare.cz/cs) was entrusted with the Granulox business in the
    Czech Republic and in Slovakia. The company specializes in medical
    products, in particular in the fields of wound management, interventional
    cardiology and radiology as well as neuroradiology. Halley Pharma Ltd.
    (http://halleypharma.com) will look after the Hungarian market in which
    they already distribute a wide array of other wound management products.

    In total there are distribution partnerships in place now for 40 countries
    worldwide, in 24 of which Granulox is already available for doctors and
    patients. In the remaining 16 countries market entry is scheduled for the
    next few months after the training of the sales force will have been
    completed, or after the local registration procedures will have been
    accomplished, respectively, which is the case in some Central and South
    American countries.

    Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
    of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
    SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
    Its purpose is to provide financing and access to the capital markets for
    the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
    subsidiary of Sangui BioTech International, Inc.

    For more information please contact:

    Joachim Fleing
    Phone: +49 (179) 7963472
    Fax: +49 (2302) 915191
    e-mail: fleing@sangui.de
    Some of the statements contained in this news release discuss future
    expectations, contain projections of results of operation or financial
    condition or state other "forward-looking" information. These statements
    are subject to known and unknown risks, uncertainties, and other factors
    that could cause the actual results to differ materially from those
    contemplated by the statements. The forward-looking information is based on
    various factors and is derived using numerous assumptions. Important
    factors that may cause actual results to differ from projections include,
    among many others, the ability of the Company to raise sufficient capital
    to meet operating requirements. Words such as "anticipates," "expects,"
    "intends," "plans," "believes," "seeks," "estimates," and variations of
    such words and similar expressions are intended to identify such
    forward-looking statements. Unless required by law, the Company undertakes
    no obligation to update publicly any forward-looking statements, whether as
    a result of new information, future events or otherwise



    ---------------------------------------------------------------------

    03.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    318529 03.02.2015


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Sangui BioTech International Inc.: SastoMed closes contracts with distribution partners in six additional markets in Eastern Europe DGAP-News: Sangui BioTech International Inc. / Key word(s): Market launch Sangui BioTech International Inc.: SastoMed closes contracts with distribution partners in six additional markets in Eastern Europe 03.02.2015 / 15:00 …